The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects

Journal of Immunology

Volumn 164, Issue 12, 2000, Pages 6276-6286

  Ågren, Lena ^a   Sverremark, Eva ^c   Ekman, Lena ^a   Schön, Karin ^a   Löwenadler, Björn ^b   Fernandez, Carmen ^c   Lycke, Nils ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; FC RECEPTOR; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; PROTEIN BCL 2; STAPHYLOCOCCUS PROTEIN A;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; FEMALE; GERMINAL CENTER; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE;

STAPHYLOCOCCUS;

EID: 0034660136     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.12.6276     Document Type: Article

References (59)

1. Woodrow, G. C. 1997. An overview of biotechnology as applied to vaccine development. In New Generation Vaccines. G. C. Woodrow, M. M. Levine, J. B. Kaper, and G. S. Cobon, eds. Marcel Decker, New York, p. 25.
2. Edelman, R. 1997. Adjuvants for the future. In New Generation Vaccines. G. C. Woodrow, M. M. Levine, J. B. Kaper, and G. S. Cobon, eds. Marcel Decker, New York, p. 173.
3. Lycke, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:504.
4. Elson, C. O. 1999. Mucosal adjuvants. In Mucosal Immunalogy. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, and J. Bienenstock, eds. Academic Press, San Diego, p. 817.
5. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clemens. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510.
6. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enteroloxin. Microbiol. Rev. 56:622.
7. Holmgren, J. 1981. Actions of cholera toxin and the prevention and treatment of cholera. Nature 292:413.
8. Merritt, E. A., and W. G. Hol. 1995. AB5 toxins. Curr. Opin. Struct. Biol. 5:165.
9. Agren, L. C., L. Ekman, B. Lowenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158:3936.
10. Agren, L., B. Lowenadler, and N. Lycke. 1998. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell Biol. 76:280.
11. Burnette, W. N., V. L. Mar, B. W. Platler, J. D. Schlotterbeck, M. D. McGinley, K. S. Stoney, M. F. Rhode, and H. R. Kaslow. 1991. Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infect. Immun. 59:4266.
12. Douce, G., M. Pizza, M. Roberts, R. Rappuoli, and G. Dougan. 1998. Mutant pertussis and Escherichia coli heat-labile toxins as adjuvants for enhancing local and systemic immune responses to coadministercd, nonliving antigens. In New Generation Vaccines. G. C. W. M. M. Levine, J. B. Kaper, and J. S. Cobon, eds. p. 253.
13. Freytag, L. C., and J. D. Clements. 1999. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236:215.
14. Yamamoto, S., Y. Takeda, M. Yamamolo, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203.
15. Douce, G., M. M. Giuliani, V. Giannelli, M. G. Pizza, R. Rappuoli, and G. Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16:1065.
16. de Haan, L., W. Verweij, E. Agsteribbe, and J. Wilschut. 1998. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. Immunol. Cell Biol. 76:270.
17. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
18. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123.
19. Agren, L. C., L. Ekman, B. Lowenadler, J. G. Nedrud, and N. Y. Lycke. 1999. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and lg-binding activity. J. Immunol. 162:2432.
20. Sverremark, E., and C. Fernandez. 1998. Role of T cells and germinal center formation in the generation of immune responses to the thymus-independent carbohydrate dextran B512. J. Immunol. 161:4646.
21. Sverremark, E., and C. Fernandez. 1998. Germinal center formation following immunization with the polysaccharide dextran B512 is substantially increased by cholera toxin. Int. Immunol. 10:851.
22. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J. V. Ravetch. 1996. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379:346.
23. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76:519.
24. Rickert, R. C., J. Roes, and K. Rajewsky. 1997. B lymphocyte-specific, Cremediated mutagenesis in mice. Nucleic Acids Res 25:1317.
25. Seppala, I., and O. Makela. 1989. Antigenicity of dextran-protein conjugates in mice: effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J. Immunol. 143:1259.
26. Hunter, R. 1970. Standardization of the chloramine-T method of protein iodination. Proc. Soc. Exp. Biol. Med. 133:989.
27. Fernandez, C., and G. Moller. 1990 Serum antibody and cellular immune response in mice to dextran B512. Cell. Immunol. 131:41.
28. Ravetch, J. V. 1997. Fc receptors. Curr. Opin. Immunol. 9:121.
29. Johansson, A., T. Sundqvist, and T. Skogh. 1988. Elimination kinetics of circulating antigens and immune complexes. III. Elimination of intravenously injected model antigens and soluble IgG immune complexes in mice. J. Clin. Lab. Immunol. 27:19.
30. Johansson, A. G., T. Lovdal, K. E. Magnusson, T. Berg, and T. Skogh. 1996. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 24:169.
31. Gardby, E., P. Lane, and N. Y. Lycke. 1998. Requirements for B7-CD28 costimulation in mucosal IgA responses: paradoxes observed in CTLA4-H γ1 transgenic mice. J. Immunol. 161:49.
32. Lees, A., F. Finkelman, J. K. Inman, K. Witherspoon, P. Johnson, J. Kennedy, and J. J. Mond. 1994. Enhanced immunogenicity of protein-dextran conjugates. 1. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules. Vaccine 12:1160.
33. Coutinho, A., G. Moller, and W. Richter. 1974. Molecular basis of B-cell activation. I. Mitogenicity of native and substituted dextrans. Scand. J. Immunol. 3:321.
34. Fernandez, C., and G. Moller. 1977. Immunological unresponsiveness to thymus-independent antigens: two fundamentally different genetic mechanisms of B-cell unresponsiveness to dextran. J. Exp. Med. 146:1663.
35. Liu, Y. J., and C. Arpin. 1997. Germinal center development. Immunol. Rev. 156:111.
36. Wang, D., S. M. Wells, A. M, Stall, and E. A. Kabat. 1994. Reaction of germinal centers in the T-cell-independent response to the bacterial polysaccharide α(1→6)dextran. Proc. Natl. Acad. Sci. USA 91:2502.
37. Kosco-Vilbois, M. H., H. Zentgraf, J. Gerdes, and J. Y. Bonnefoy. 1997. To 'B' or not to 'B' a germinal center? Immunol. Today 18:225.
38. Zheng, B., S. Han, and G. Kelsoe. 1996. T helper cells in murine germinal centers are antigen-specific emigrants that downregulate Thy-1. J. Exp. Med. 184:1083.
39. Stedra, J., and J. Cerny. 1994. Distinct pathways of B cell differentiation. I. Residual T cells in athymic mice support the development of splenic germinal centers and B cell memory without an induction of antibody. J. Immunol. 152: 1718.
40. Secord, E. A., L. V. Rizzo, E. W. Barroso, D. T. Umetsu, G. J. Thorbecke, and R. H. DeKruyff. 1996. Reconstitution of germinal center formation in nude mice with Th1 and Th2 clones. Cell. Immunol. 174:173.
41. Roberts, T., and E. C. Snow. 1999. Cutting edge: recruitment of the CD19/CD21 coreceptor to B cell antigen receptor is required for antigen-mediated expression of Bcl-2 by resting and cycling hen egg lysozyme transgenic B cells. J. Immunol. 162:4377.
42. Lycke, N. Y. 1993. Cholera toxin promotes B cell isotype switching by two different mechanisms. J. Immunol. 150:4810.
43. Lycke, N., and J. Holmgren. 1989. Adoptive transfer of gut mucosal antitoxin memory by isolated B cells one after oral immunization with cholera toxin. Infect. Immun. 57:1137.
44. Lycke, N., E. Severinson, and W. Strober. 1990. Cholera toxin acts synergistically with 1L-4 to promote IgG1 switch differentiation. J. Immunol. 145:3316.
45. Agren, L., M. Norin, N. Lycke, and B. Lowenadler. 1999. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD. Protein Engin. 12:173.
46. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161:4115.
47. Leonetti, M., R. Thai, J. Cotton, S. Leroy, P. Drevet, F. Ducancel, J. C. Boulain, and A. Menez. 1998. Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting. J. Immunol. 160:3820.
48. Löwenadler, B., and N. Lycke. 1994. Fusion proteins with heterologous T helper epitopes: recombinant E. coli heat-stable enterotoxin proteins. Int. Rev. Immunol. 11:103.
49. Skea, D. L., and B. H. Barber. 1993. Studies of the adjuvant-independent antibody response to immunotargeting: target structure dependence, isotype distribution, and induction of long term memory. J. Immunol. 151:3557.
50. Snider, D. P., and D. M. Segal. 1989. Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, FcγRII, and B220 molecules on murine splenic B cells. J. Immunol. 143:59.
51. Baixeras, E., E. Garcia-Lozano, and A. C. Martinez. 1996. Decrease in cAMP levels promoted by CD48-CD2 interaction correlates with inhibition of apoptosis in B cells. Scand. J. Immunol. 43:406.
52. Lycke, N., A. K. Bromander, L. Ekman, U. Karlsson, and J. Holmgren. 1989. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J. Immunol. 142:20.
53. Warner, G. L., S. Davies, and D. W. Scott. 1989. Cholera toxin-sensitive and insensitive signaling via surface Ig. J. Immunol. 143:458.
54. Klaus, G. G., K. Vondy, and M. Holman. 1987. Selective effects of cholera toxin on the activation of mouse B cells by different polyclonal activators. Eur. J. Immunol. 17:1787.
55. Muthusamy, N., A. R. Baluyut, and B. Subbarao. 1991. Differential regulation of surface Ig-and Lyb2-mediated B cell activation by cyclic AMP. I. Evidence for alternative regulation of signaling through two different receptors linked to phosphatidylinositol hydrolysis in murine B cells. J. Immunol. 147:2483.
56. Venkataraman, C., R. L. Chelvarajan, J. C. Gambier, and S. Bondada. 1998. Interleukin-4 overcomes the negative influence of cyclic AMP accumulation on antigen receptor stimulated B lymphocytes. Mol. Immunol. 35:997.
57. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective upregulation of B7.2 expression. J. Immunol. 159:5301.
58. Hörnqvist, E., and N. Lycke. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:2136.
59. Simmons, C., G. J. Maestroni, P. Fowler, M. Ghaemmaghami, N. Lycke, M. Pizza, R. Rappuoli, and G. Dougan. 1999. MHC-class I restricted cytotoxic lymphocyte responses induced by enterotoxin-based adjuvants. J. Immunol. 163:6502.